Eric K. Singhi, MD
7yr CROWN update of 1L lorlatinib 55% progression-free at 7 YEARS. Median PFS STILL not reached. In metastatic solid tumors, this is essentially unheard of. Let that sink in. And hopefully, one day, this becomes the standard (or even better) for ALL metastatic cancers.#ASCO26
